|Articles|June 5, 2015

DIA Highlighted Sessions

Author(s)Applied Clinical Trials Editorial Staff

Some can't miss sessions for the upcoming meeting.

Bringing Clinical Trial Practices into the 21st Century

The Development of Patient Power: From Consumer to Active Participant!

Disruptive Forces in Health Care Innovation: Where Are They Leading Us?

Breakthrough Medicines or Affordable Health Care: Do We Have to Choose?

Operationalizing the Pragmatic Clinical Trial: The Role of PCORI and the Pharmaceutical Industry

International Regulatory Convergence: Collaboration, Cooperation and Global Governance

The Future of Clinical Trial Data Sharing

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Trending on Applied Clinical Trials Online

FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

DIA Highlighted Sessions

Related Content

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

Breaking the Efficacy Ceiling in IBD and Beyond

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

How to Tell Substance from Branding in Biotech's Support Ecosystem

Trending on Applied Clinical Trials Online

FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

Breaking the Efficacy Ceiling in IBD and Beyond

ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap